Hemostasis Valve Market Size & Share 2025 - 2034

Hemostasis Valve Market Size

The global hemostasis valve market was estimated at USD 180.2 million in 2024. The market is expected to grow from USD 189.3 million in 2025 to USD 304.6 million by 2034 at a CAGR of 5.4% during the forecast period. A hemostasis valve is a type of medical device used during minimally invasive procedures. It allows healthcare professional to insert and move tools such as catheters, guidewires into the body without letting blood leak out.

The rising prevalence of cardiovascular diseases (CVDs) is a major factor stimulating the growth of the hemostasis valve market. Conditions such as coronary artery disease, heart failure, and peripheral artery disease have become significant health issues, accelerated by the factors such as growing aging population, poor diet, and sedentary lifestyle. For instance, according to the report from the World Health Federation (WHF), in 2021, 20.5 million deaths were surged globally due to cardiovascular diseases (CVD), with 80% of these deaths occurring in low- and middle-income countries.
 

Thus, as the incidence of these diseases rises, so does the need for cardiovascular interventions such as coronary angioplasties, stent insertions, and heart valve replacements increases. Hemostasis valves are important in these procedures, specifically in catheter-based interventions, where they help to manage blood flow and prevent bleeding at the catheter insertion site. The increasing number of patients undergoing these procedures creates the demand for high-performance hemostasis valves that ensure accurate blood flow control and improve surgical outcomes.
 

The growing demand for minimally invasive surgeries (MIS) is key catalyst for the rising adoption of hemostasis valves, specifically in fields such as cardiology and neurology. These valves are important in maintaining hemostatic control, allowing smooth insertion and manipulation of catheters and guidewires during the procedures. For example, companies such as Merit Medical Systems has launched their phD hemostasis valve which has advanced features such as sealing capabilities and enhanced pressure resistance, making it safer and more effective in performance with complex interventions. Thus, continuous technological advancement are escalating the integration of high-performance hemostasis valves to meet the growing clinical and procedural demands of minimally invasive surgeries.
 

Hemostasis Valve Market Trends

• Technological advancement in hemostasis valves has substantially enhanced performance, safety, and adaptability in minimally invasive procedures. Modern innovative hemostasis valves are now designed with new advanced sealing mechanisms to minimize blood loss, which includes a wide range of catheter size, and also help to maintain pressure stability during high-stress interventions.
   
• In addition to this, the development of rotating hemostasis valves (RHS) which are integrated for one handed operations, this innovation helps clinicians to handle devices with improved control and also minimize the procedural time. Further, the integration of radiopaque materials enhances visibility under fluoroscopy, helping in accurate placement.
   
• For example, the Guardian II Hemostasis Valve is engineered with an 8 Fr. inner lumen and star-shaped seal technology to independently secure multiple devices reduces blood loss during interventions.
   
• Moreover, emerging haemostasis valves are now integrated with high pressure injections and allows multiple catheter insertion without wear out. Some of the valves have Y-shaped connectors which has more than one opening, thus used in complex procedures such as neurovascular and heart procedure.
   
• A notable example of this is Boston Scientific's WATCHDOG Hemostasis Valve which is design for maximizes performance with a unique cross-slit design to minimize leakage, an 8F inner lumen for use with multiple devices and an added thumb rest for maximum comfort. Thus, such advancements in hemostasis valve are accelerating the growth of the market.
   

Trump Administration Tariffs

• In future, if potential future tariffs are placed on imports from key manufacturing countries such as China could rise the cost of production of hemostasis valves. These tariffs could also affect to supply chain disruptions, as many manufacturers in the market depends on cost-effective Chinese suppliers for specialized materials and subassemblies.
   
• Because of this, companies operating in the hemostasis valve market may need to re-examine and adapt their sourcing and manufacturing strategies to mitigate the risks associated with overreliance in a single geographic region. To minimize the risk, manufacturers may start buying from other countries market such as India, Malaysia, Vietnam, or other countries in Eastern Europe.
   
• In the short term, manufacturers may face some problems such as delays in deliveries, higher cost of production, and also delays in customer support and services. Thus, over time these efforts could help companies to build a strong and more flexible supply chain that will not just dependent on one country.
   

Hemostasis Valve Market Analysis

Based on product type, the market is divided into hemostasis valve Y-connectors, double Y-connector hemostasis valves, one-handed hemostasis valves, and other product types. The global market held a revenue of 171.7 million in 2023. The hemostasis valve Y-connectors segment held revenues of USD 72 million in the year 2024 and the segment is poised for significant growth at a CAGR of 5.4% during the forecast period.
 

• Y-connectors are important in medical procedures because of their versatility specifically in complex surgeries, wherein simultaneous access to multiple devices or catheters are necessary. This functionality of Y connectors allows healthcare providers to effectively manage the flow of blood, while minimizing the blood loss. Which is important in high-stakes surgeries including cardiovascular or endovascular procedures.
   
• The rising preference for minimally invasive procedures further escalated the demand for Y-connectors, as they allow for more precise control and fewer incisions. Additionally, innovations in Y-connectors design, such as improved sealing mechanisms and durability, have increased their reliability, making them even more appealing in clinical settings.
   
• For instance, B. Braun’s rotating hemostasis valve Y-Connector includes a side port that can rotate independently and also has a large 9.5 F Lumen with a large thumb wheel and a rotating swivel luer connector providing ergonomic handling and flexibility during interventions.
   
• Furthermore, many hemostasis valves with Y-connectors now include transparent or radiopaque housings which allows visual monitoring of blood flow and air bubbles. This enhances procedural safety, especially during contrast injections. Thus, this advancements helps in creating more demand for Y-connectors and contributing to growth in the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the hemostasis valve market is bifurcated into angiography and angioplasty. The angiography segment held a significant revenue of USD 115.7 million in 2024 with a revenue share of 64.2%.
 

• The rising number of angiography procedures plays an important role in the dominance of the angiography segment in the global market. For instance, according to National Center for Biotechnology Information, coronary angiography (CAG) remains the gold standard imaging method for diagnosing obstructive coronary artery disease (CAD), with approximately 4 million angiograms performed annually in Europe and the U.S.
   
• Hemostasis valves are necessary in these procedures as they ensure the safe insertion and removal of catheters while preventing any blood loss.
   
• Further, during the angiography, catheters are inserted into the vascular system to inject contrast media and visualize blood vessels. Thus, in this hemostasis valves ensures a tight seal around these catheters, which is estimated to reach USD 54.7 billion by 2032, minimizes the blood loss throughout the procedure.
   
• Moreover, the increasing adoption of advanced angiographic techniques, such as coronary and cerebral angiography, creates the demand for valves that provide reliable sealing and ease of use, strengthening the dominance of the angiography application segment in the market.
   

Based on end use, the hemostasis valve market is bifurcated into hospitals, ambulatory surgical centers (ASCs), and other end users. The hospitals segment dominated the global market accounting for USD 108.7 million in 2024.
 

• The growth of the segment is owing to the ability of the hospitals to manage large numbers of patients requiring interventional and diagnostic procedure for vascular access management. For instance, hospitals have specialized units, such as cardiology, neurology, where angiography, catheterization and minimally invasive surgeries are routinely performed. For this procedures hemostasis valves are necessary for maintaining the flow of blood.
   
• Further, the rising cases of cardiovascular diseases, neurological disorders and the increasing number of patients visiting hospitals for diagnostic and interventional care are boosting the demand for hemostasis valve.
   
• Additionally, the growing demand for rapid, in-hospital procedures such as angioplasty, embolization and neuro interventions has created the need for hemostasis valves.  Hospitals are well-positioned to implement this technologies, because of the availability of highly skilled healthcare professionals. Thus, this segment remains in the forefront of the rapidly evolving market.

The North America hemostasis valve market is accounted for USD 73.6 million revenues in 2024 forecasted to reach USD 124.7 million by 2034. The U.S. dominated the North America market with the largest revenue of USD 63.2 million in 2023.
 

• The rising incidence of chronic disorders such as cardiovascular diseases, neurological disorders in the U.S., is accelerating the demand for the hemostasis valves.
   
• For instance, in 2021, as per the data from the Centers for Disease Control and Prevention (CDC), reports that heart disease remains the leading cause of death for men, women, and individuals across most racial and ethnic groups in the U.S. In 2022 alone, approximately 702,880 deaths were attributed to heart disease, accounting for 1 in every 5 deaths nationwide.
   
• Thus, this rising burden of the cardiovascular diseases is propelling the market growth in the U.S. as many companies, hospitals and research institutes are undertaking various research to develop advanced hemostasis valve solutions to the combat the disease in the country.
   
• Additionally, substantial healthcare expenditure and ongoing technological advancements in hemostasis valves further solidify the growth of the market in U.S.
   

Europe: The hemostasis valve market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The country’s well established healthcare system and the rising demand for accurate and efficient hemostasis valve are the key factors stimulating the growth of the market in the country.
   
• Moreover, the growing aging population base is further solidifying the growth of the market in the country.
   
• For instance, as per the data from the Office for National Statistics, the elderly population of the UK is expected to rise significantly. In 2020, an estimated 2.5% of the total population comprised of people aged 85 and over, by 2040 the figure is projected to reach 4.3% of the total population.
   

Asia Pacific: Japan hemostasis valve market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has one of the fastest aging populations globally. As per estimates, Japan has around 36.25 million people aged 65 years and above, which leads to one-third of the entire Japanese population.
   
• Further, the rising incidence of cardiovascular diseases in Japan is accelerating the market growth. For instance, according to the report from World Heart Federation, Japan reported 372,483 deaths due to cardiovascular diseases (CVD) in 2019.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policy makers for the need for effective strategies to overcome the disease and its related health conditions.
   

Middle East and Africa: The hemostasis valve market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The increasing need for hemostasis valve are further fueled by public health campaigns and national screening initiatives, resulting in significant market growth in the region.
   
• In addition, Vision 2030’s focus on healthcare modernization is boosting investments in hemostasis valves, supported by the need for advanced diagnostics in managing chronic diseases such as neurological disorders and cardiovascular conditions.
   

Hemostasis Valve Market Share

The top 4 players of the market account for approximately 45% of the market share which includes companies such as Abbott Laboratories, B. Braun Melsungen, Boston Scientific, Nipro Medical, among others. These companies maintain their dominance in the market through innovative product launches, extensive distribution networks and strong regulatory approval.
 

Moreover, strategic partnerships with research institutes, and government agencies play a primary role in advancing the development of advanced hemostasis valve and getting the necessary permits. The development of public awareness about chronic diseases and its health impact through the social media platform, will encourage more individuals to seek the diagnosis and treatment, enabling market players to strengthen their position in this growing sector.
 

Hemostasis Valve Market Companies

Some of the eminent market participants operating in the hemostasis valve industry include:

• Argon Medical Devices
• Abbott Laboratories
• B. Braun Melsungen
• Beijing Demax Medical Technology
• Boston Scientific
• DeRoyal Industries
• Freudenberg Medical
• Lepu Medical Technology
• Merit Medical Systems
• Nipro Medical
• SCW Medicath
• Shenzhen Antmed
• Teleflex
• Terumo
• Vygon
   
• Abbott Laboratories has strong geographical presence which enables it to enhance its market reach. Abbott Laboratories operates in more than 160 countries thus comprising of a robust distribution network.
   
• Boston Scientific Corporation has a strong product portfolio leading to larger adoption and significant market expansion. Boston specializes in hemostasis valve, such as WATCHDOG hemostasis valve.
   
• Nipro Medical invests in research & development, fostering innovation and growth. The company continuously evolves with the newest advancement in hemostasis valve.
   

Hemostasis Valve Industry News:

• In April 2023, Abbott announced the completion of its acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company. The acquisition strengthened Abbott's position in the cardiovascular sector, particularly in the treatment of peripheral and coronary artery disease.
   
• In April 2021, Nipro Medical Corporation (NMC) announced the creation of a Vascular Division in the U.S., which included a range of advanced technologies and innovative vascular and cardiovascular products. The division aimed to provide clinicians with improved procedural and imaging solutions that enhanced patient care. This strategic initiative benefited Nipro by broadening its product portfolio and reinforcing its position in the highly competitive U.S. medical device market.
   

The hemostasis valve market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Hemostasis valve Y-connectors
• Double Y-connector hemostasis valves
• One-handed hemostasis valves
• Other product types

Market, By Application

• Angiography
• Angioplasty

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE